Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Lindsey Jacobson"'
Autor:
Lindsey Jacobson, Scott Ferguson
Publikováno v:
Volume 3B: 48th Design Automation Conference (DAC).
Designers have historically used existing solutions as a baseline for modifying and improving the next generation solution. However, it is also possible that certain design solutions are pursued by designers irrelevant of previous design history, sug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::150209d931ff73daffe9b813bf2b788b
https://doi.org/10.1115/detc2022-91348
https://doi.org/10.1115/detc2022-91348
Autor:
Lindsey Jacobson, Scott Ferguson
Publikováno v:
Volume 3B: 47th Design Automation Conference (DAC).
The operating conditions for, and requirements of, a product may change in unexpected ways while it is in service. Products incapable of meetings these new requirements lose value. This reduction in value diminishes the user experience or product rep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b4585455aab08fc701e8158427fc78df
https://doi.org/10.1115/detc2021-71913
https://doi.org/10.1115/detc2021-71913
Autor:
Madhu Sanga, Claudine S. Oelke, Strahs Andrew, Monette M. Cotreau, William Slichenmyer, Lindsey Jacobson, Christine Hale, Dennis L. Vargo, Robert G. Kochan
Publikováno v:
Clinical pharmacology in drug development. 1(3)
Objective To evaluate the absorption, metabolism, and excretion of tivozanib, a new investigational drug for renal cell carcinoma and solid malignancies. Methods Eight healthy male participants received a single 1.5-mg (˜160 μCi) dose of oral [(14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cf6a8d00cb3cba86609fd92d002aec
https://pubmed.ncbi.nlm.nih.gov/27121337
https://pubmed.ncbi.nlm.nih.gov/27121337
Autor:
El Noh, Ann-Shung Lieu, Gregory A. Helm, Gerald R. Hankins, Lindsey Jacobson, Jin Zhong Li, Debra D. Pittman, Hongwei Li, John A. Chiorini
Publikováno v:
Tissue Engineering. 12:209-219
The osteogenic potential of AAV5hBMP6 was compared with that of ADhBMP6 in immunodeficient and immunocompetent rats. AAV5hBMP6 (2.3 x 10(12) particles) and ADhBMP6 (5 x 10(7) PFU) elicited viral antibody production in immunocompetent rats. Among rats
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d5d366b73c35ac728973b4a11629241
https://doi.org/10.1089/ten.2006.12.209
https://doi.org/10.1089/ten.2006.12.209
Autor:
Lindsey Jacobson, Gregory A. Helm, Dwight Saulle, Gerald R. Hankins, Hongwei Li, An-Hsiang Liu, El Noh, Jin Zhong Li
Publikováno v:
Molecular Therapy. 9:S338-S339
Although adenoviral vectors have a very broad range and high efficiency of cell transduction both in vitro and in vivo, the uses of adenoviral vectors have been significantly limited in immunocompetent animals. We tested whether the amount of protein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a41ae7ca4533902f0c58dd0478feadf7
https://doi.org/10.1016/j.ymthe.2004.06.795
https://doi.org/10.1016/j.ymthe.2004.06.795
Autor:
Kathleen N. Moore, Lindsey Jacobson, Manpreet K. Chadha, Jeffrey R. Infante, Monette M. Cotreau, Andrew Strahs, William Slichenmyer, Dennis L. Vargo
Publikováno v:
Journal of Clinical Oncology. 30:445-445
445 Background: Tivozanib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors-1, -2, and -3 that is currently being tested in a Phase III study in patients with renal cell carcinoma and Phase I/II studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36d214cff5b611724f043a49ed80376d
https://doi.org/10.1200/jco.2012.30.5_suppl.445
https://doi.org/10.1200/jco.2012.30.5_suppl.445
Autor:
Claudine S. Oelke, Andrew Strahs, Dennis L. Vargo, Monette M. Cotreau, Robert G. Kochan, Christine Hale, William Slichenmyer, Lindsey Jacobson
Publikováno v:
Molecular Cancer Therapeutics. 10:C123-C123
Background: Tivozanib is a potent, selective, long half-life tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3. Tivozanib has demonstrated antitumor activity in a Phase II study in subjects with ren
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::92a52329b871757f326b6bb11a48cf15
https://doi.org/10.1158/1535-7163.targ-11-c123
https://doi.org/10.1158/1535-7163.targ-11-c123
Autor:
Kathleen N. Moore, Jeffrey R. Infante, Manpreet Chadha, Lindsey Jacobson, Andrew Strahs, Dennis L. Vargo, William Slichenmyer, Monette M. Cotreau
Publikováno v:
Molecular Cancer Therapeutics. 10:C121-C121
Background: Tivozanib is a potent, selective, long half-life tyrosine kinase inhibitor of vascular endothelial growth factor receptors-1, -2, and -3 that is currently being tested in a Phase III study in patients with renal cell carcinoma and Phase I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3726531f08efff5a8c22669f45daf5a5
https://doi.org/10.1158/1535-7163.targ-11-c121
https://doi.org/10.1158/1535-7163.targ-11-c121
Autor:
El Noh, Jin Zhong Li, Hongwei Li, Gregory A. Helm, John A. Chriorini, Lindsey Jacobson, Dwight Saulle, Gerald R. Hankins, An-Hsiang Liu
Publikováno v:
Molecular Therapy. 9:S339
Adeno-associated virus (AAV) and adenovirus (AD) are the two most commonly viral vectors in gene therapy. Both vectors have their own advantages and limitations. In this study, a human bone morphogentic protein 6 (hBMP6) cDNA under control of an imme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4220f3c0e3eba9ef39d8baf47d5923a
https://doi.org/10.1016/j.ymthe.2004.06.796
https://doi.org/10.1016/j.ymthe.2004.06.796
Autor:
Jin Zhong Li, Hongwei Li, Gerald R. Hankins, Ann-Shung Lieu, El Noh, Lindsey Jacobson, Debra D. Pittman, John A. Chiorini, Gregory A. Helm
Publikováno v:
Tissue Engineering; Feb2006, Vol. 12 Issue 2, p209-219, 11p